UNITY Biotechnology (UBX) IPO Opens 12% Higher

Today's IPO for UNITY Biotechnology, Inc. (NASDAQ: UBX) opened for trading at $19 after pricing 5,000,000 shares of common stock at a public offering price of $17.

The Company has also granted the underwriters a 30-day option to purchase from the Company an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Goldman Sachs & Co. LLC, Morgan Stanley and Citigroup acted as joint book-running managers for the offering. Mizuho Securities acted as a lead manager for the offering.

UNITY Biotechnology is developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions, such as osteoarthritis, eye diseases and pulmonary diseases. UNITY's seasoned management team has experience building companies and developing medicines.

You May Also Be Interested In